Planta Med 2001; 67(6): 489-500
DOI: 10.1055/s-2001-16496
Original Papers
© Georg Thieme Verlag Stuttgart · New York

Extracts from Fruits of Saw Palmetto (Sabal serrulata) and Roots of Stinging Nettle (Urtica dioica): Viable Alternatives in the Medical Treatment of Benign Prostatic Hyperplasia and Associated Lower Urinary Tracts Symptoms

Egon Koch
  • Dr. Willmar Schwabe Arzneimittel GmbH, Department of Pharmacology, Karlsruhe, Germany
Further Information

Publication History

September 29, 2000

March 10, 2001

Publication Date:
17 August 2001 (online)


Benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms (LUTS) are very common disorders in aging men. Despite the great clinical importance, many aspects of their aetiology remain uncertain although it is generally accepted that advanced age and testicular androgens are important requirements for the development of these complaints. The currently available therapeutic options include watchful waiting, changes of life style, medical treatments and invasive therapies. In many European countries the use of phytopharmaceuticals for the management of BPH and related LUTS is common and these products represent up to 80 % of all drugs prescribed for this disorder. In particularly, extracts from the fruits of saw palmetto (Sabal serrulata, syn. Serenoa repens) and the roots of stinging nettle (Urtica dioica) are popular. During the last years numerous papers have been published which elaborated on the pharmacological activities and the clinical assessment of these herbal remedies. These investigations have not only broadened the scientific basis for the rational use of phytotherapeutics but have also provided evidence for their therapeutic efficacy and favourable safety profile.


AR:androgen receptor

bFGF:basic fibroblast growth factor

BPH:benign prostatic hyperplasia

CK:creatine kinase


EGF:epidermal growth factor

ER:estrogen receptor

HLE:human leukocyte elastase

HPLC:high pressure liquid chromatography

HSOR:hydroxysteroid oxidoreductase

IGF:insulin-like growth factor

IPSS:international prostate symptome scale

LTB4:leukotriene B4

LUTS:lower urinary tract symptoms

p.o.:per os

PDGF:platelet-derived growth factor

PgR:progesterone receptor

PLA2:phospholipase A2


SHBG:sex hormone-binding globulin

SNRE:stinging nettle root extract

SPFE:saw palmetto fruit extract

TGF:transforming growth factor

TXB2:thromboxan B2

UDA:Urtica dioica agglutinin

UGS:urogenital sinus


  • 1 Oesterling J E. Benign prostatic hyperplasia. Medical and minimally invasive treatment options.  New England Journal of Medicine. 1995;  332 99-109
  • 2 Wilt T J, Ishani A, Stark G, MacDonald R, Lau J, Mulrow C. Saw palmetto extracts for treatment of benign prostatic hyperplasia. A systematic review.  Journal of the American Medical Association. 1998;  280 1604-9
  • 3 Abrams P. New words for old: Lower urinary tract symptoms for ”prostatism”.  British Medical Journal. 1994;  308 929-30
  • 4 Weisser H, Krieg M. Die benigne Prostatahyperplasie - das Ergebnis einer altersbedingten Entgleisung der Androgen-Estrogen-Balance.  Urologe [A]. 1997;  36 3-9
  • 5 Weckermann D, Wawroschek F. Medikamentöse Therapie des benignen Prostatahyperplasie-Syndroms.  Münchner Medizinische Wochenschrift. 1999;  141 54-8
  • 6 Buck A C. Phytotherapy for the prostate.  British Journal of Urology. 1996;  78 325-36
  • 7 Schneider B, Sökeland J. Phytotherapie bei benigner Prostatahyperplasie (BPH) - Ergebnisse einer Umfrage.  Urologe [B]. 1997;  37 113-5
  • 8 Lowe F C, Ku J C. Phytotherapy in treatment of benign prostatic hyperplasia. A critical review.  Urology. 1996;  48 12-20
  • 9 Braun M, Derakhshani P, Zumbé J, Engelmann U. Die Behandlung der benignen Prostatahyperplasie mit Extrakten der Sabal serenoa .  Urologe [B]. 1998;  38 37-41
  • 10 Plosker G L, Brogden R N. Serenoa repens (Permixon®). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia.  Drugs and Aging. 1996;  9 379-95
  • 11 Rittmaster R S. Finasteride.  New England Journal of Medicine. 1994;  330 120-5
  • 12 Sultan C, Terraza A, Devillier C, Carilla E, Briley M, Loire C, Descomps B. Inhibition of androgen metabolism and binding by a liposterolic extract of ”Serenoa repens B” in human foreskin fibroblasts.  Journal of Steroid Biochemistry. 1984;  20 515-9
  • 13 Düker E -M, Kopanski L, Schweikert H U. Inhibition of 5α-reductase activity by extracts from Sabal serrulata .  Planta Medica. 1989;  55 587
  • 14 Breu W, Stadler F, Hagenlocher M, Wagner H. Der Sabalfrucht-Extrakt SG 291. Ein Phytotherapeutikum zur Behandlung der benignen Prostatahyperplasie.  Zeitschrift für Phytotherapie. 1992;  13 107-15
  • 15 Hagenlocher M, Romalo G, Schweikert H U. Spezifische Hemmung der 5α-Reduktase durch einen neuen Extrakt aus Sabal serrulata .  Aktuelle Urologie. 1993;  24 146-9
  • 16 Weisser H, Tunn S, Behnke B, Krieg M. Effect of the Sabal serrulata extract IDS 89 and its subfractions on 5α-reductase activity in human benign prostatic hyperplasia.  Prostate. 1996;  28 300-6
  • 17 Iehlé C, Délos S, Guirou O, Tate R, Raynaud J P, Martin P M. Human prostatic steroid 5α-reductase isoforms - A comparative study of selective inhibitors.  Journal of Steroid Biochemistry and Molecular Biology. 1995;  54 273-9
  • 18 Délos S, Carsol J L, Ghazarossian E, Raynaud J P, Martin P M. Testosterone metabolism in primary cultures of human prostate epithelial cells and fibroblasts.  Journal of Steroid Biochemistry and Molecular Biology. 1995;  55 375-83
  • 19 Bayne C W, Donnelly F, Ross M, Habib F K. Serenoa repens (Permixon): A 5α-reductase types I and II inhibitor - new evidence in a coculture model of BPH.  Prostate. 1999;  40 232-41
  • 20 Koch E, Biber A. Pharmakologische Wirkungen von Sabal- und Urticaextrakten als Grundlage für eine rationale medikamentöse Therapie der benign Prostatahyperplasie.  Urologe [B]. 1994;  34 90-5
  • 21 Koch E. Pharmakologie und Wirkmechanismus von Extrakten aus Sabalfrüchten (Sabal fructus), Brennesselwurzeln (Urtica radix) und Kürbissamen (Cucurbitae peponis semen) bei der Behandlung der benignen Prostatahyperplasie. In: Loew D, Rietbrock N, editors Phytopharmaka in Forschung und klinischer Anwendung. Darmstadt; Steinkopff 1995: 57-79
  • 22 Niederprüm H J, Schweikert H U, Zänker K S. Testosterone 5α-reductase inhibition by free fatty acids from Sabal serrulata fruits.  Phytomedicine. 1994;  1 127-33
  • 23 Weisser H, Krieg M. Fatty acid composition of phospholipids in epithelium and stroma of human benign prostatic hyperplasia.  Prostate. 1998;  36 235-43
  • 24 Palin M F, Faguy M, LeHoux J G, Pelletier G. Inhibitory effects of Serenoa repens on the kinetic of pig prostatic microsomal 5α-reductase activity.  Endocrine. 1998;  9 65-9
  • 25 Fitzpatrick J M, Lynch T H. Phytotherapeutic agents in the management of symptomatic benign prostatic hyperplasia.  Urologic Clinics of North America. 1995;  22 407-12
  • 26 Rhodes J, Primka R L, Berman C, Vergult G, Gabriel M, Malice MPL Gibelin B. Comparison of finasteride (Proscar®), a 5α-reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5α-reductase inhibition.  Prostate. 1993;  22 43-51
  • 27 Kyprianou N, Isaacs J T. Quantal relationship between prostatic dihydrotestosterone and prostatic cell content: critical threshold concept.  Prostate. 1987;  11 41-50
  • 28 Strauch G, Perles P, Vergult G, Gabriel M, Gibelin B, Cummings S, Malbecq W, Malice M P. Comparison of finasteride (Proscar®) and Serenoa repeus (Permixon®) in the inhibition of 5-alpha reductase in healthy male volunteers.  European Urology. 1994;  26 247-52
  • 29 Di Silverio F, Monti S, Sciarra A, Varasano P A, Martini C, Lanzara S, D’Eramo G, Di Nicola S, Toscano V. Effects of long-term treatment with Serenoa repens (Permixon®) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia.  Prostate. 1998;  37 77-83
  • 30 Stenger A, Tarayre J P, Carilla E, Delhon A, Charveron M, Morre M, Lauressergues H. Ètude pharmacologique et biochimique de l’extrait hexanique de Serenoa repens B (PA109*).  Gazette Médicale de France. 1982;  89 2041-8
  • 31 Carilla E, Briley M, Fauran F, Sultan C, Duvilliers C. Binding of Permixon, a new treatment for prostatic benign hyperplasia, to the cytosolic androgen receptor in the rat prostate.  Journal of Steroid Biochemistry. 1984;  20 521-3
  • 32 Odenthal K P, Rauwald H W. Kontraktionshemmende Eigenschaften von lipophilem Extrakt aus Sabal serrulata .  Aktuelle Urologie. 1996;  27 152-8
  • 33 Gutierrez M, Hidalgo A, Cantabrana B. Spasmolytic activity of a lipidic extract from Sabal serrulata fruits: Further study of the mechanisms underlying this activity.  Planta Medica. 1996;  62 507-11
  • 34 Gutierrez M, García de Boto M J, Cantabrana B, Hidalgo A. Mechanisms involved in the spasmolytic effect of extracts from Sabal serrulata fruit on smooth muscle.  General Pharmacology. 1996;  27 171-6
  • 35 Goepel M, Hecker U, Krege S, Rübben H, Michel M C. Saw palmetto extracts potently and noncompetitively inhibit human α1-adrenoceptors in vitro .  Prostate. 1999;  38 208-15
  • 36 Habenicht U F, El Etreby M F. Rationale for using aromatase inhibitors to manage benign prostatic hyperplasia.  Journal of Andrology. 1991;  12 395-402
  • 37 Kuiper G GJM, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson J A. Cloning of a noval estrogen receptor in rat prostate and ovary.  Proceedings of the National Academy of Sciences of the United States of America. 1996;  93 5925-30
  • 38 Chang W Y, Prins G S. Estrogen receptor-β: Implications for the prostate gland.  Prostate. 1999;  40 115-24
  • 39 Di Silverio F, D’Eramo G, Lubrano C, Flammia G P, Sciarra A, Palma E, Caponera M, Sciarra F. Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients.  European Urology. 1992;  21 309-14
  • 40 Elghamry M I, Hänsel R. Activity and isolated phytoestrogen of shrub palmetto fruits (Serenoa repens Small), a new estrogenic plant.  Experentia. 1969;  25 828-9
  • 41 Helpap B. Pathologie der chronischen unspezifischen Prostatis. In: Vahlensieck W, Rutishauser G, editors Benigne Prostatopathien. Stuttgart; Thieme 1992: 35-50
  • 42 Theyer G, Kramer G, Assmann I, Sherwood E, Preinfalk W, Marberger M, Zechner O, Steiner G E. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia.  Laboratory Investigations. 1992;  66 96-107
  • 43 Hiermann A. Über Inhaltsstoffe von Sabalfrüchten und deren Prüfung auf entzündungshemmende Wirkung.  Archiv der Pharmazie. 1989;  322 111-4
  • 44 Breu W, Hagenlocher M, Redl K, Tittel G, Stadler F, Wagner H. Antiphlogistische Wirkung eines mit hyperkritischem Kohlendioxid gewonnenen Sabalfrucht-Extraktes.  Arzneimittel Forschung/Drug Research. 1992;  42 547-51
  • 45 Paubert-Braquet M, Mencia-Huerta J M, Cousse H, Braquet P. Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon®) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils.  Prostaglandins, Leukotrienes and Essential Fatty Acids. 1997;  57 299-304
  • 46 Taryare J P, Delhon A, Lauressergues H, Stenger A, Barbara M, Bru M, Villanova G, Caillol V, Aliaga M. Action antiodémasteuse d’un extrait hexanique de drupes de Sereno repens Bartr.  Annales Pharmaceutiques Franciases. 1983;  41 559-70
  • 47 Culig Z, Hobisch A, Cronauer M V, Radmayr C, Hittmair A, Zhang J, Thumher M, Bartsch G, Klocker H. Regulation of prostatic growth and function by peptide growth factors.  Prostate. 1996;  28 6, 392-405
  • 48 Kessler O J, Keisari Y, Servadio C, Abramovici A. Role of chronic inflammation in the promotion of prostatic hyperplasia in rats.  Journal of Urology. 1998;  159 1049-53
  • 49 Paubert-Braquet M, Cousse H, Raynaud J P, Mencia-Huerta J M, Braquet P. Effect of the lipidosterolic extract of Serenoa repens (Permixon) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies.  European Urology. 1998;  33 340-7
  • 50 Ravenna L, Di Silverio F, Russo M A, Salvatori L, Morgante E, Morrone S, Cardillo M R, Russo A, Frati L, Gulino A, Petrangeli E. Effects of the lipidosterolic extract of Serenoa repens (Permixon) on human prostatic cell lines.  Prostate. 1996;  29 219-30
  • 51 Paubert-Braquet M, Richardson F O, Servent-Saez N, Gordon W C, Monge M C, Bazan N G, Authie D, Braquet P. Effect of Serenoa repens extract (Permixon) on estradiol/testosterone-induced experimental prostate enlargement in the rat.  Pharmaceutical Research. 1996;  34 171-9
  • 52 Otto U, Wagner B, Becker H, Schröder S, Klosterhalfen H. Transplantation of human benign hyperplastic prostate tissue into nude mice: First results of systematic therapy.  Urologia Internationalis. 1992;  48 167-70
  • 53 Vacher P, Prevarskaya N, Skryma R, Audy M C, Vacher A M, Odessa M F, Dufy B. The lipidosterolic extract from Serenoa repens interferes with prolactin receptor signal transduction.  Journal of Biomedical Science. 1995;  2 357-65
  • 54 Weisser H, Behnke B, Helpap B, Bach D, Krieg M. Enzyme activities in tissue of human benign prostatic hyperplasia after three months treatment with the Sabal serrulata extract IDS 89 (Strogen®) or placebo.  European Urology. 1997;  31 97-101
  • 55 Penning T M, Carlson K E, Sharp R B. Affinity labelling of anti-inflammatory drug and prostaglandin-binding site of 3α-hydroxysteroid dehydrogenase of rat liver cytosol with 17β- and 21-bromoacetoxysteroid.  Biochemical Journal. 1987;  245 269-76
  • 56 Helpap B, Oehler U, Weisser H, Bach D, Ebeling L. Morphology of benign prostatic hyperplasia after treatment with sabal extract IDS 89 or placebo.  Journal of Urologic Pathology. 1995;  3 175-82
  • 57 Casarosa C, Cosci o di Coscio M, Fratta M. Lack of effects of a lyposterolic extract of Serenoa repens on plasma levels of testosterone, follicle-stimulating Hormone, and luteinizing hormone.  Clinical Therapeutics. 1988;  10 585-8
  • 58 De Bernardi di Valserra M, Tripodi A S, Contos S, Germogli R. Sereno repens capsules: A bioequivalence study.  Acta Toxicologica et Therapeutica. 1994;  15 21-39
  • 59 Chevalier G, Benard P, Cousse H, Benogne T. Distribution study of radioactivity in rats after oral administration of the lipido/sterolic extract of Serenoa repens (Permixon®) supplemented with [1 - 14 C]-lauric acid, [1 - 14 C]-oleic acid or [1 - 14 C]-β-sitosterol.  European Journal of Drug Metabolism and Pharmacokinetics. 1997;  22 73-83
  • 60 Lowe F C, Dreikorn K, Borkowski A, Braeckman J, Denis L, Ferrari P, Gerber G, Levin R, Perrin P, Stenge T. Review of recent placebo-controlled trials utilizing phytotherapeutic agents for treatment of BPH.  Prostate. 1998;  37 187-93
  • 61 Lowe F C, Fagelman E. Phytotherapy in the treatment of benign prostatic hyperplasia: An update.  Urology. 1999;  53 671-8
  • 62 Metzker H, Kieser M, Hölscher U. Wirksamkeit eines Sabal-Urtica-Kombinationspräparats bei der Behandlung der benignen Prostatahyperplasie (BPH).  Urologe [B]. 1996;  36 292-300
  • 63 Sökeland J, Albrecht J. Kombination aus Sabal- und Urticaextrakt vs. Finasterid bei BPH (Stad. I bis II nach Alken). Vergleich der therapeutischen Wirksamkeit in einer einjährigen Doppelblindstudie.  Urologe [A]. 1997;  36 327-33
  • 64 Rückle E. Brennesselwurzeltee bei beginnender Prostatitis. Hippokrates Stuttgart; 1950: 55-6
  • 65 Frank B, Bohn I, Uehleke B. Urtica. In: Blaschek W, Hänsel R, Keller K, Reichling J, Rimpler G, Schneider G, editors Hagers Handbuch der Pharmazeutischen Praxis, Folgeband 3, Drogen L-Z. 1998: 710-36
  • 66 Bauer H W, Sudhoff F, Dressler S. Endokrine Parameter während der Behandlung der benignen Prostatahyperplasie mit ERU. In: Bauer HW, editor Benigne Prostatahyperplasie II. München; Zuckerschwerdt 1988: 44-9
  • 67 Kraus R, Spiteller G, Bartsch W. (10E,12Z)-9-Hydroxy-10,12-octadecadiensäure, ein Aromatase-Hemmstoff aus dem Wurzelextrakt von Urtica dioica . Liebigs Annalen der Chemie. 1991: 335-9
  • 68 Ganßer D, Spiteller G. Aromatase inhibitors from Urtica dioica roots.  Planta Medica. 1995;  61 138-40
  • 69 Pöch G. Combined Effects of Drugs and Toxic Agents. Wien; Springer 1993
  • 70 Wagner H, Willer F, Samtleben R, Boos G. Search for the antiprostatic principle of stinging nettle (Urtica dioica) roots.  Phytomedicine. 1994;  1 213-24
  • 71 Wolff H, Bezold G, Zebhauser M, Meurer M. Impact of clinically silent inflammation on male genital tract organs as reflected by biochemical markers in semen.  Journal of Andrology. 1991;  12 331-4
  • 72 Reinhardt A, Haidl G, Schill W B. Granulocyte elastase indicates silent male genital tract inflammation and appropriate anti-inflammatory treatment.  Andrologia. 1997;  29 187-92
  • 73 Pelova N. Changes of collagen and elastic fibers in involution of the prostate gland.  Arkhiv Patologii. 1969;  31 61-5
  • 74 Djavan B, Seitz C, Kramer G, Kaplan P, Richier J, Marberger M, McConnell J D. Elastin gene expression in benign prostatic hyperplasia.  Prostate. 1999;  40 242-7
  • 75 Koch E, Jaggy H, Chatterjee S S. Inhibition of human leukocyte elastase by an ethanolic extract from roots of the stinging nettle (Urtica dioica L.)  Naunyn-Schmiedeberg’s Archiv of Pharmacology. 1995;  351 R57
  • 76 Ablin R J. Immunological aspects of benign prostatic hyperplasia. In: Hinman jr. F, editor Benign Prostatic Hypertrophy. New York; Springer 1983: 73-98
  • 77 Anderson R U. Immunologische Aspekte der chronischen Prostatitis. In: Vahlensieck W, Rutishauser G, editors Benigne Prostatopathien. Stuttgart; Thieme 1992: 51-4
  • 78 Steiner G, Gessl A, Kramer G, Schöllhammer A, Parich A, Marberger M. Local T-cell-activation signals an ongoing immune response in BPH.  Aktuelle Urologie. 1992;  23 55
  • 79 Rook G AW, Hernandes R, Lightman S L. Hormones, peripherally activated prohormones and regulation of the Th1/Th2 balance.  Immunology Today. 1994;  15 301-3
  • 80 Wagner H, Willer F. Neue chemische und pharmakologische Untersuchungen des Radix-Urticae-Extraktes (ERU). In: Bauer HW, editor Benigne Prostatahyperplasie II. München; Zuckschwerdt 1988: 51-4
  • 81 Peumans W J, De Ley M, Broekaert W. An unusual lectin from stinging nettle (Urtica dioica) rhizomes.  FEBS Letters. 1984;  177 99-103
  • 82 LeMoal M A, Truffa-Bachi P. Urtica dioica agglutinin, a new mitogen for murine T lymphocytes: Unaltered interleukin-1 production but late interleukin-2-mediated proliferation.  Cellular Immunology. 1988;  115 24-35
  • 83 Wagner H, Willer F. Chemie und Pharmakologie von Urtica-Präparaten.  Natur- und Ganzheitsmedizin. 1990;  3 309-12
  • 84 Rovira P, Buckle M, Abastado J P, Peumans W J, Truffa-Bachi P. Major histocompatibility class I molecules present Urtica dioica agglutinin, a superantigen of vegetal origin, to T lymphocytes.  European Journal of Immunology. 1999;  29 1571-80
  • 85 Musette P, Galelli A, Chabre H, Callard P, Peumans W, Truffa-Bachi P, Kourilsky P, Gachelin G. Urtica dioica agglutinin, a Vbeta 8.3-specific superantigen, prevents the development of the systemic lupus erythematosus-like pathology of MRL lpr/lpr mice.  European Journal of Immunology. 1996;  26 1707-11
  • 86 Wagner H, Geiger W N, Boos G, Samtleben R. Studies on the binding of Urtica dioica agglutinin (UDA) and other lectins in an in vitro epidermal growth factor receptor test.  Phytomedicine. 1995;  4 287-90
  • 87 Enderle-Schmitt U, Gutschank W M, Aumüller G. Wachstumskinetik von Zellkulturen aus BPH unter Einfluß von Extractum radicis urticae (ERU). In: Bauer HW, editor Benigne Prostatahyperplasie II. München; Zuckschwerdt 1988: 56-61
  • 88 Rausch U, Aumüller G, Eicheler W, Gutschank W, Beyer G, Ulshöfer B. Der Einfluß von Phytopharmaka auf BPH-Gewebe und Explantatkulturen in vitro . In: Rutishauser G, editor Prostatahyperplasie II. München; Zuckschwerdt 1992: 117-24
  • 89 Konrad L, Müller H H, Lenz C, Laubinger H, Aumüller G, Lichius J J. Antiproliferative effect on human prostate cancer cells by a stinging nettle root (Urtica dioica) extract.  Planta Medica. 2000;  66 44-7
  • 90 Lichius J J, Lenz C, Lindemann P, Müller H H, Aumüller G, Konrad L. Antiproliferative effect of a polysaccharide fraction of a 20 % methanolic extract of stinging nettle roots upon epithelial cells of the human prostate (LNCaP).  Pharmazie. 1999;  54 768-71
  • 91 Chung L WK, Matsuura J, Rocco A K, Thompson T C, Miller G H, Runner M N. Tissue interactions and prostatic growth: A new mouse model for prostatic hyperplasia.  Annals of the New York Academy of Sciences. 1984;  438 393-404
  • 92 Lichius J J, Muth C. The inhibiting effects of Urtica dioica root extracts on experimentally induced prostatic hyperplasia in the mouse.  Planta Medica. 1997;  63 307-10
  • 93 Lichius J J, Renneberg H, Blaschek W, Aumüller G, Muth C. The inhibiting effects of components of stinging nettle roots on experimentally induced prostatic hyperplasia in mice.  Planta Medica. 1996;  65 666-8
  • 94 Daube G. Pilotstudie zur Behandlung der benignen Prostatahyperplasie bei Hunden mit Extractum radicis urticae (ERU). In: Bauer HW, editor Benigne Prostatahyperplasie II. München; Zuckschwerdt 1988: 63-6
  • 95 Farnsworth W E. Roles of estrogen and SHBG in prostate physiology.  Prostate. 1996;  28 17-23
  • 96 Schmidt K. Die Wirkung eines Radix Urticae-Extrakts und einzelner Nebenextrakte auf das SHBG des Blutplasmas bei der benignen Prostatahyperplasie.  Fortschritte der Medizin. 1983;  101 713-6
  • 97 Ganßer D, Spiteller G. Plant constituents interfering with human sex hormone-binding globulin. Evaluation of a test method and its application to Urtica dioica root extracts.  Zeitschrift für Naturforschung. 1995;  50c 98-104
  • 98 Schröttner G, Ganßer D, Spiteller G. Lignans from the roots of Urtica dioica and their metabolites bind to human sex hormone binding globulin (SHBG).  Planta Medica. 1997;  63 529-32
  • 99 Hryb D J, Khan M S, Romas N A, Rosner W. The effect of extracts of the roots of the stinging nettle (Urtica dioica) on the interaction of SHBG with its receptor on human prostatic membranes.  Planta Medica. 1995;  61 31-2
  • 100 Farnsworth W E. Na+, K+-ATPase: The actual androgen receptor of the prostate?.  Medical Hypotheses. 1993;  41 358-62
  • 101 Hirano T, Homma M, Oka K. Effects of stinging nettle root extracts and their steroidal components on the Na+,K+-ATPase of the benign prostatic hyperplasia.  Planta Medica. 1994;  60 30-3
  • 102 Vontobel H P, Herzog R, Rutishauser G, Kres H. Ergebnisse einer Doppelblindstudie über die Wirksamkeit von ERU-Kapseln in der konservativen Behandlung der benignen Prostatahyperplasie.  Urologe [A]. 1985;  24 49-51
  • 103 Dathe G, Schmid H. Phytotherapie der benignen Prostatahyperplasie (BPH). Doppelblind Studie mit Extraktum Radicis Urticae.  Urologe [B]. 1987;  27 223-6
  • 104 Engelmann U, Boos G, Kres H. Therapie der benignen Prostatahyperplasie mit Bazoton Liquidum.  Urologe [B]. 1996;  36 287-91

Dr. Egon Koch

Department of Pharmacology

Dr. Willmar Schwabe Arzneimittel GmbH

Willmar-Schwabe-Straße 4

76227 Karlsruhe



Fax: +49(0)721-4005 150